Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab

Eur J Intern Med. 2020 Apr:74:115-116. doi: 10.1016/j.ejim.2019.12.011. Epub 2020 Jan 9.

Authors

Martin Michaud¹, Florian Catros², Francis Gaches²

Affiliations

¹ Department of Internal Medicine, Joseph Ducuing Hospital, 15 rue Varsovie, Toulouse 31076, France. Electronic address: mmichaud@hjd.asso.fr.
² Department of Internal Medicine, Joseph Ducuing Hospital, 15 rue Varsovie, Toulouse 31076, France.

PMID: 31926783
DOI: 10.1016/j.ejim.2019.12.011

No abstract available

Keywords: C reactive protein; Giant cell arteritis; Polymyalgia rheumatica; Relapse; Serum amyloid A; Tocilizumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Giant Cell Arteritis*
Humans
Polymyalgia Rheumatica*
Serum Amyloid A Protein

Substances

Antibodies, Monoclonal, Humanized
Serum Amyloid A Protein
tocilizumab